Jie Liu, Shuang Li, Fan Yang, Tianyu Li, Rui Li, Yousuf Waheed, Chen Meng, Shulin Li, Kun Liu, Yanshan Tong, Haisheng Xu, Chuankuo Tian, Xinglei Zhou
BACKGROUND/AIMS: Roxadustat, an oral medication for treating renal anemia, is a hypoxia-inducible factor prolyl hydroxylase inhibitor used for regulating iron metabolism and promoting erythropoiesis. To investigate the efficacy and safety of roxadustat in patients undergoing peritoneal dialysis (PD) with erythropoietin hyporesponsiveness. METHODS: Single-center, retrospective study, 81 PD patients (with erythropoietin hyporesponsiveness) were divided into the roxadustat group (n = 61) and erythropoiesis-stimulating agents (ESAs) group (n = 20)...
April 23, 2024: Korean Journal of Internal Medicine